Abacavir & Lamivudine, Aidovudine (Trizvir)
|
|
Systemic anti-infective
|
|
Antiretroviral agent
|
|
HIV-1 infection
|
|
1. Adults: <40kg: not recommended. กร40kg: 1 tab twice daily. 2. Children: Not recommended.
|
|
Category C
|
|
GI upset, anorexia, insomnia, lab abnormalities (anemia, neutropenia, elevated liver enzymes and CPK, mild hyperglycemia, elevated triglycerides), headache, malaise, myopathy, myositis, neuropathy, lactic acidosis, severe hepatomegaly with steatosis, hypersensitivity reactions (may be fatal), nasal symptoms, cough, fever/chills, depression, fat redistribution, rash (may be severe, eg, Stevens-Johnson), dizziness, myalgia, arthralgia, post-treatment exacerbation of hepatitis, immune reconstitution syndrome
|
Pregnancy Risk Categories defined:
A: Studies in pregnant women failed to show a risk to the fetus in the first
trimester - with no evidence of risk in the later trimesters.
B: Animals studies indicate no adverse effect to the fetus, but there are no adequate,
clinical studies in pregnant women.
C: Animal studies have shown an adverse effect on the fetus, but there are no adequate,
clinical studies in humans. Despite potential risks, the drug may be useful in pregnant
women.
D: There is evidence of risk to the human fetus, but the potential benefits of use in
pregnant women may be acceptable, despite potential risks.
X: Studies in animals or humans show fetal abnormalities, or adverse reaction reports
indicate evidence of fetal risk. Warning: the risks involved clearly outweigh any
potential benefit from using the drug in pregnant women, regardless of trimester.
NR: Not rated (i.e., no information available at this time as to the potential
risks or benefits).
|
|
|
|